anti-tau vectorized mAbs AAV-based delivery (Voyager Therapeutics)

N/A

Report date: 2025/01/26 18:20:50

Base Information

Drug Nameanti-tau vectorized mAbs AAV-based delivery (Voyager Therapeutics)
Drug Alias Nameanti-tau vectorized mAbs AAV-based delivery (Voyager Therapeutics/AbbVie)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsNerve DegenerationAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVoyager Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesVoyager Therapeutics Inc
Inactive CompaniesAbbvie Inc
Active IndicationsNerve DegenerationAlzheimer Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A